NeuroPace Reports Q3 2026 Results with Revenue Decline and Lowered Full-Year Guidance
NeuroPace (NPCE) reported third-quarter revenue of $23.1 million, a slight decrease from $23.4 million in the prior year period. While RNS System revenue grew 1.4% year-over-year to $22.9 million, it fell short of management's expectations due to operational issues at several large accounts. Despite the revenue dip, the company achieved an adjusted EBITDA gain of $400,000, a significant improvement from last year's loss. The company issued a downward revision for its full-year 2026 total revenue guidance, now projecting $91 million to $92 million compared to the previous range of $99.5 million to $101.5 million. However, management remains optimistic about long-term growth, targeting RNS revenue growth of up to 20% by the end of 2027 and highlighting a massive market opportunity in adolescent focal epilepsy.
Topics: gross margin improvement guidance revision operating expenses revenue decline